Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E27.63 EPS (ttm)2.01 Insider Own0.10% Shs Outstand1.68B Perf Week-2.31%
Market Cap93.28B Forward P/E18.63 EPS next Y2.98 Insider Trans-2.60% Shs Float1.67B Perf Month-4.71%
Income3.37B PEG1.59 EPS next Q0.67 Inst Own70.20% Short Float0.75% Perf Quarter11.60%
Sales18.47B P/S5.05 EPS this Y-22.30% Inst Trans0.15% Short Ratio1.24 Perf Half Y-25.72%
Book/sh9.34 P/B5.94 EPS next Y4.12% ROA10.30% Target Price62.53 Perf Year-10.50%
Cash/sh3.31 P/C16.78 EPS next 5Y17.42% ROE22.70% 52W Range48.71 - 76.09 Perf YTD-4.42%
Dividend1.56 P/FCF- EPS past 5Y-12.20% ROI4.60% 52W High-27.07% Beta1.02
Dividend %2.81% Quick Ratio1.30 Sales past 5Y-3.20% Gross Margin75.70% 52W Low13.92% ATR1.04
Employees25000 Current Ratio1.50 Sales Q/Q21.00% Oper. Margin24.70% RSI (14)34.82 Volatility1.60% 1.55%
OptionableYes Debt/Eq0.44 EPS Q/Q71.10% Profit Margin18.20% Rel Volume0.69 Prev Close56.07
ShortableYes LT Debt/Eq0.37 EarningsJan 26 BMO Payout75.40% Avg Volume10.07M Price55.49
Recom2.30 SMA20-4.93% SMA50-2.37% SMA200-10.70% Volume6,901,877 Change-1.03%
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Jan-19-17 08:59PM  Bristol-Myers Won't Seek Accelerated Opdivo Lung Cancer OK
07:33PM  Bristol-Myers Falls Further Behind Merck in Lung Cancer Race at Bloomberg
06:49PM  Bristol-Myers won't seek accelerated Opdivo lung cancer approval Reuters
06:30PM  Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer Business Wire
03:08PM  U.S. top court to hear Bristol-Myers out-of-state injury appeal Reuters
09:00AM  Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study Business Wire
08:39AM  Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?
Jan-18-17 12:12PM  Trump health pick Price defends investments, Obamacare replacement Reuters
08:30AM  AstraZeneca Offers Update on Immuno-Oncology Program
06:00AM  Trump's health pick set to defend investments at U.S. Senate hearing Reuters
Jan-17-17 04:32PM  FDA Track Record Bodes Well For Merck Keytruda Plus Chemo: Leerink
09:59AM  Why Bristol-Myers Squibb May Be a Merger Target Soon
Jan-16-17 10:14AM  These 5 Drug Patents Will Expire in 2017 at Investopedia
Jan-13-17 10:45AM  Bristol-Myers Squibb Co. Value Analysis (NYSE:BMY) : January 13, 2017
09:06AM  Mylans Recent Commercial and Product Developments
Jan-12-17 05:10PM  Trumps HHS nominee has promised to divest from these Mass. companies at bizjournals.com
04:04PM  Bristol-Myers Threatens Merck's 'Head Start' In Lung Cancer: Analyst
02:00PM  Eli Lilly Rebounds On Chemo-Drug Patent Win Vs. Generic Teva
09:55AM  3 Charts Every Bristol-Myers Squibb Shareholder Needs to See at Motley Fool
09:54AM  Merck: News So Good Three Analysts Had to Upgrade It at Barrons.com
07:57AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : January 12, 2017
07:35AM  Trump criticism leads to falling stock prices at these Tampa employers at bizjournals.com
Jan-11-17 04:33PM  Bristol-Myers and AstraZeneca Take Beatings -5.30%
01:59PM  Trump's Comments Slam Drug Stocks at The Wall Street Journal
01:03PM  2 Stocks For a Trump-ed Up Pharma Market at Barrons.com
12:28PM  Merck Lung-Cancer Drug May Get OK For Large Patient Population
10:29AM  Merck: One Giant Leap at Barrons.com
10:10AM  Merck boosts Dow, Amazon prime members get a new perk, ADM to buy pet food producer
09:52AM  Merck leapfrogs rivals in lung cancer drug combination race Reuters
Jan-10-17 08:23AM  Here's a Biotech IPO You'll Want to Watch at Motley Fool
Jan-09-17 08:11AM  Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study
Jan-08-17 07:25AM  5 Tough Questions for Bristol-Myers Squibb's CEO at Motley Fool
Jan-06-17 06:16PM  Cramer's game plan: Banks will be in hog heaven next week at CNBC
11:01AM  It Was CheckMate for Bristol-Myers Squibb Company in 2016 at Motley Fool
09:42AM  2 Big Reasons Merck & Co., Inc. Stock Surged 11% in 2016 at Motley Fool
08:17AM  Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
08:15AM  Blog Coverage Five Prime Announced Extension of Collaboration Agreement by Bristol-Myers Squibb Accesswire
07:24AM  Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View
06:59AM  Bristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration Business Wire
Jan-05-17 05:59PM  Final Trade: BMY, FXI & more
03:09PM  Crystal Ball Gazing: Biotech Predictions For 2017 at Forbes
12:36PM  Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio
09:43AM  The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016 at Motley Fool
09:10AM  The Scariest Thing About Bristol-Myers Squibb's Dividend at Motley Fool
08:13AM  Bristol-Myers Extends Deal with Five Prime Therapeutics
06:59AM  Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo (nivolumab) in Combination with Darzalex (daratumumab) Business Wire
Jan-04-17 05:16PM  Deutsche Bank to pay $95 mln to end U.S. tax fraud case Reuters
04:05PM  Five Prime Therapeutics and Bristol-Myers Squibb Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways GlobeNewswire
09:01AM  Bristol-Myers Trades Ex-Dividend Wednesday at Investopedia
06:25AM  4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017
Jan-03-17 09:18AM  Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference Business Wire
Jan-01-17 11:09AM  3 Biggest Risks for Bristol-Myers Squibb in 2017 at Motley Fool
Dec-30-16 06:05PM  What Factors Are Contributing to Gilead Sciences Growth?
09:27AM  ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong
09:07AM  How GlaxoSmithKlines Pharmaceuticals Segment Has Performed
Dec-29-16 09:00AM  Bristol-Myers Squibb to Take Part at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top Business Wire
07:36AM  Will Keytrudas Position Strengthen in the Lung Cancer Market?
02:00AM  Bristol-Myers, Tiffany among NYC companies lauded for environmental, social values at bizjournals.com
Dec-28-16 07:48AM  Bristol-Myers Squibb draws upside bet
Dec-27-16 09:07AM  Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up
Dec-24-16 03:37PM  If You're in Your 40s, Consider Buying These Stocks at Motley Fool
Dec-23-16 05:35PM  Why Portola Pharmaceuticals Inc Stock Surged Higher Today at Motley Fool
02:32PM  Gilead Sciences, Inc. (GILD) Is A Hail Mary: 3 Better Stocks To Consider at Insider Monkey
12:41PM  Something Strange Is Going On With Oral Insulin
05:48AM  Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe
Dec-22-16 10:37AM  Bristol-Myers Squibbs Opdivo May See Strong Demand in 2016
10:22AM  Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo
09:06AM  Positive Results from CheckMate-227 Trial May Boost Opdivos Position
07:36AM  Pomalyst Still Dominates the Third-Line Multiple Myeloma Segment
07:36AM  Opdivo Is a Key Growth Driver for Bristol-Myers Squibb in 2016
Dec-21-16 08:42PM  [$$] Business Watch at The Wall Street Journal
06:05PM  Revlimid Continues to Be a Key Growth Driver for Celgene in 2016
04:41PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
11:02AM  [$$] Bristol-Myers Names CEO as New Chairman at The Wall Street Journal
10:37AM  BMYs Hepatitis C Franchise May See a Drop in Revenues in 2016
09:07AM  Baraclude Faces Declining Revenues in 2016
08:49AM  Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy
08:40AM  Bristol-Myers Squibb CEO will serve as chairman, too at MarketWatch
08:30AM  Giovanni Caforio Named Chairman of Bristol-Myers Squibbs Board of Directors Business Wire
08:15AM  Blog Coverage Bristol-Myers Squibb Signs Pre-clinical Stage, "armed" Virus Deal with PsiOxus Accesswire
07:36AM  Bristol-Myers Squibb Plans to Strengthen Its Operating Model in 2017
06:59AM  Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma GlobeNewswire
06:59AM  Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma Business Wire
03:51AM  Ono warns on profit after govt halves price of cancer drug Opdivo
Dec-20-16 05:31PM  Bristol-Myers Squibb Expects Strong Revenue Growth in 2016
11:19AM  [$$] Pharma Picks as Fundamentals Weaken at Barrons.com
10:36AM  Bristol-Myers Squibb Co (BMY) And Pfizer Inc. (PFE) Agree To $50 Million Loan To Portola Pharmaceuticals Inc (PTLA) at Insider Monkey
09:14AM  Bristol-Myers Commits Up to $1 Billion for Virus 'Armed' to Fight Tumors
06:59AM  Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an Armed Oncolytic Virus to Address Solid Tumors Business Wire
Dec-19-16 04:14PM  Incyte Could Step Onto Auction Block With Strong Jakafi Sales: RBC
04:14PM  Bristol-Myers Will Gain In Lung Cancer Square-Off Vs. Merck: Jefferies
02:06PM  Why Jefferies Upgraded Bristol-Myers, Cut Merck at Barrons.com
01:27PM  The Juice is Nearly Loose for Bristol-Myers, Ritholtz's Brown Contends
12:49PM  'I Didn't Buy This Call,' Jim Cramer Says of Merck Downgrade
12:20PM  Portola Pharma Wins on Pfizer and Bristol-Myers Loan Agreement
11:51AM  The 12 Greatest Medical Breakthroughs of 2016 at Motley Fool
09:55AM  Japan to review drug prices annually rather than every two years -sources Reuters
09:09AM  Jefferies' Huge Pharma Pair Trade: Bristol-Myers Upgraded To Buy, Merck Downgraded To Sell
08:55AM  Top Analysts Upgrades and Downgrades: Anadarko Petroleum, Bristol-Myers, Comcast, Disney, Merck and More at 24/7 Wall St.
08:16AM  Analysts' Actions -- Bristol-Myers, Merck, United Technologies and More
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elicker John ESVP, Public Affairs & IRJan 03Option Exercise0.00950056,232Jan 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4030192,801Dec 06 04:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000187,794Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorNov 01Option Exercise22.14305,9096,772,825998,777Nov 03 05:22 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494055,505Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorOct 11Option Exercise17.51368,7066,456,042692,868Oct 13 05:00 PM
ANDREOTTI LAMBERTODirectorSep 08Sale56.9710,800615,276323,699Sep 09 04:41 PM
ANDREOTTI LAMBERTODirectorSep 07Sale56.7710,800613,116334,499Sep 09 04:41 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,596029,722Sep 07 04:33 PM
ANDREOTTI LAMBERTODirectorAug 25Sale58.9211,600683,472345,299Aug 25 05:10 PM
ANDREOTTI LAMBERTODirectorAug 24Sale59.4311,600689,359356,899Aug 25 05:10 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,511015,250Aug 03 04:56 PM
ANDREOTTI LAMBERTODirectorJul 08Sale75.0411,600870,461368,499Jul 11 05:12 PM
ANDREOTTI LAMBERTODirectorJul 07Sale73.8611,600856,776380,099Jul 11 05:12 PM
Blin EmmanuelSVP, Chief Strategy OfficerJul 02Option Exercise0.00951012,516Jul 06 05:58 PM
Cuss Francis MEVP & CSOJul 01Option Exercise0.003,6550291,628Jul 06 05:58 PM
Gordon MurdoEVP, Chief Commercial OfficerJul 01Option Exercise0.002,335014,950Jul 06 05:58 PM
ANDREOTTI LAMBERTODirectorJun 29Sale72.799,800713,342392,194Jun 30 05:42 PM
ANDREOTTI LAMBERTODirectorJun 28Sale71.6713,400960,396390,394Jun 30 05:42 PM
Elicker John ESVP, Public Affairs & IRJun 14Sale72.6911,820859,21955,011Jun 16 04:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMay 20Sale70.7930,2012,137,838184,694May 24 05:04 PM
Caldarella Joseph CSVP & ControllerMay 16Sale72.473,519255,00455,238May 17 04:46 PM
Caforio GiovanniChief Executive OfficerMay 05Option Exercise0.008,0400134,549May 09 04:42 PM
Caforio GiovanniChief Executive OfficerMay 03Option Exercise24.7950,4551,250,602145,958May 05 04:31 PM
Caforio GiovanniChief Executive OfficerMay 03Sale71.3134,5942,466,885117,118May 05 04:31 PM
ANDREOTTI LAMBERTODirectorMay 02Option Exercise26.04234,7206,112,787671,514May 04 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyMay 02Sale71.9522,2181,598,65221,971May 04 05:28 PM
ANDREOTTI LAMBERTODirectorMay 02Sale71.88234,72016,870,792436,794May 04 05:28 PM
ANDREOTTI LAMBERTODirectorApr 05Sale66.0011,600765,626436,794Apr 06 04:18 PM
ANDREOTTI LAMBERTODirectorApr 04Sale65.7911,600763,216448,394Apr 06 04:18 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554025,260Apr 05 04:59 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0031,624055,059Mar 14 09:44 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0037,1430300,492Mar 14 09:43 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00204,4470574,101Mar 14 09:43 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,860074,177Mar 14 09:43 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0020,460067,864Mar 14 09:44 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,406089,478Mar 14 09:42 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0060,6230132,906Mar 14 09:42 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0057,4840366,730Mar 14 09:42 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,435032,069Mar 14 09:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.008,806059,091Mar 14 09:41 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0075,6180247,158Mar 14 09:41 PM
Blin EmmanuelSVP, Head of CommercializationMar 10Option Exercise0.0011,707013,498Mar 14 09:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 10Option Exercise0.0019,309019,608Mar 14 09:41 PM
CAMPBELL LEWIS BDirectorMar 08Option Exercise24.962,50062,4002,500Mar 10 04:36 PM
CAMPBELL LEWIS BDirectorMar 08Sale66.002,500165,0000Mar 10 04:36 PM
Caforio GiovanniChief Executive OfficerMar 06Option Exercise0.002,889079,627Mar 08 04:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 06Option Exercise0.001,28202,611Mar 08 04:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724050,821Mar 08 04:43 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931048,253Mar 08 04:43 PM
LEUNG SANDRAEVP, General CounselMar 06Option Exercise0.005,5740315,121Mar 08 04:41 PM
Elicker John ESVP, Public Affairs & IRMar 06Option Exercise0.001,043053,715Mar 08 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100269,043Mar 08 04:42 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,391060,032Mar 08 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3240169,885Mar 08 04:40 PM
Blin EmmanuelSVP, Head of CommercializationMar 06Option Exercise0.0081901,553Mar 08 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528024,746Mar 08 04:40 PM
Caldarella Joseph CSVP & ControllerMar 04Sale64.6412,962837,91646,322Mar 07 05:41 PM
Caforio GiovanniChief Executive OfficerFeb 17Option Exercise22.8920,125460,66188,778Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Option Exercise22.7314,560330,949319,699Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Sale63.5710,152645,342309,547Feb 19 04:32 PM
Caforio GiovanniChief Executive OfficerFeb 17Sale63.5812,040765,52776,738Feb 19 04:32 PM
ANDREOTTI LAMBERTODirectorFeb 04Option Exercise0.00148,1800445,820Feb 08 04:31 PM
Paliwal Dinesh CDirectorFeb 01Option Exercise0.003,25703,257Feb 03 06:28 PM